Overview
- Mechanisms of resistance to endocrine therapies in ER positive breast cancer
- ER-independent pathways important in advanced therapy resistant breast cancer
- Transcription factors in cancer
- Epigenetic and transcriptional reprogramming in cancer
- Identification of novel therapeutic options for endocrine resistant breast cancer
- Computational Biology
COLLABORATORS
Dr. Jennifer M. Rosenbluth, Dana-Farber Cancer Institute, Boston, MA
Dr. Iros Barozzi, Imperial College London
Research Student Supervision
2 students, MRes Biomedical Research. 2018-2020